×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Welcome to Day Two and Session 5: Plenary Session: CRISPR Cures
Session Chair(s)
Scott Henry, PhD
Vice President, Nonclinical Development
Ionis Pharmaceuticals, Inc., United States
CRISPR Cures: Actionable Nonclinical, CMC, and Regulatory Paths to Building Gene Editing Therapies for N=Many on a Platform of N=Rare
Speaker(s)
Speaker
Fyodor Urnov, PhD
Innovative Genomics Institute , United States
Scientific Director
Have an account?